Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

about

Real-world evaluation of compliance and preference in Alzheimer's disease treatment: an observational study in Taiwan.

P2860

Q36766861-CDAE7B8A-5AA0-473B-B7AE-6019DCCC39E2

P2860

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

Item

http://www.wikidata.org/entity/Q36264977

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

@ast

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

@en

type

Item

label

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

@ast

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

@en

prefLabel

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

@ast

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

@en

P1476

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

@en

P2093

A V Srinivasan

http://www.w3.org/2001/XMLSchema#string

Jae-Hong Lee

http://www.w3.org/2001/XMLSchema#string

Ming-Chyi Pai

http://www.w3.org/2001/XMLSchema#string

Nagaendran Kandiah

http://www.w3.org/2001/XMLSchema#string

Nazem Bassil

http://www.w3.org/2001/XMLSchema#string

Ozgur Yuksel

http://www.w3.org/2001/XMLSchema#string

Shelley diTommaso

http://www.w3.org/2001/XMLSchema#string

P2860

Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies

Adherence to Medication

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Risk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain).

Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice.

Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

Pharmacokinetic rationale for the rivastigmine patch.

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

P304

1779-1787

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CIA.S85319

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hany M Aref

P577

2015-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26622172

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4639476

http://www.w3.org/2001/XMLSchema#string

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

about

P2860

P2860

Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932